Search Results for 'Rbv-Hcv'

Rbv-Hcv published presentations and documents on DocSlides.

Daclatasvir + Sofosbuvir + RBV in GT3

Daclatasvir + Sofosbuvir + RBV in GT3

by sophia2

. with Advanced Liver Disease. ALLY-3+ Study. Phas...

PEG alfa-2a RBV versus

PEG alfa-2a RBV versus

by alexa-scheidler

. PEG alfa-. 2a . versus. INF RBV . APRICOT S...

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

by trish-goza

IAPAC African Regional Capacity-Building Hub. Bas...

HCV Clinical Management TRAINER(S)

HCV Clinical Management TRAINER(S)

by danika-pritchard

IAPAC African Regional Capacity-Building Hub. Bas...

Prevention strategies for HIV/HCV co infection

Prevention strategies for HIV/HCV co infection

by giovanna-bartolotta

Isabelle Andrieux-Meyer, MD. Médecins Sans Front...

Future HCV Treatment Paradigms

Future HCV Treatment Paradigms

by kittie-lecroy

Mark Sulkowski, MD . Professor of Medicine. Medic...

FISSION Design Objective

FISSION Design Objective

by travis

Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

by webraph

Sameh W. Boktor, MD, MPH. Medical Epidemiologist. ...

Hepatitis C Imtiaz Alam, M.D.

Hepatitis C Imtiaz Alam, M.D.

by olivia-moreira

Medical Director, Austin Hepatitis Center. 1. Hep...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by myesha-ticknor

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by cheryl-pisano

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

Management of Patients with Chronic Hepatitis C: The Route to Safe and Effective Care

by lois-ondreau

Sameh W. Boktor, MD, MPH. Medical Epidemiologist....

OBV/PTV/r DSV RBV OBV/PTV/r

OBV/PTV/r DSV RBV OBV/PTV/r

by ellena-manuel

DSV . placebo. Randomisation*. Partial blind. 1...

Peginterferon alfa-2a +

Peginterferon alfa-2a +

by stefany-barnette

RBV . versus. Interferon alfa. -. 2a + RBV . ACT...

by ellena-manuel

Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...

by tawny-fly

RBV . versus. . PEG alfa-. 2a . versus. INF + R...

by marina-yarberry

OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...

Hepatitis C Drug Pipeline

Hepatitis C Drug Pipeline

by cheryl-pisano

HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...

Direct Acting Antivirals: What are they? What is their pl

Direct Acting Antivirals: What are they? What is their pl

by tawny-fly

Mark Sulkowski, MD. Associate Professor of Medici...

David Fletcher, MD

David Fletcher, MD

by tatiana-dople

Department of Medicine. University of Toronto. Co...

Out With the Old and In With the New, Again?

Out With the Old and In With the New, Again?

by test

Out With the Old, In With the New. Current Standa...

by celsa-spraggs

Morris Sherman MD . BCh. PhD FRCP(C) . Associate...

HIV and HCV Update for the Pharmacist – June 2014

HIV and HCV Update for the Pharmacist – June 2014

by marina-yarberry

John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...

by natalia-silvester

OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...

Current strategies for the management of treatment naïve a

Current strategies for the management of treatment naïve a

by min-jolicoeur

Mark S. Sulkowski, MD. Medical Director, Viral He...

EASL 2019 HCV Conference Update

EASL 2019 HCV Conference Update

by sophia

April 10. –14. , 2019. Vienna, Austria. Disclaim...

HIV-HCV Coinfection in the era of effective antiviral therapy

HIV-HCV Coinfection in the era of effective antiviral therapy

by mia

Mark Sulkowski, . MD. Professor of Medicine. Medic...

Use of HCV DAAs with HIV Regimens

Use of HCV DAAs with HIV Regimens

by robaut

Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....

Management of HCV in Co-Infected Patients

Management of HCV in Co-Infected Patients

by danika-pritchard

Marie-Louise Vachon, MD, . MSc. Division of . Inf...

Update on the HCV Antiviral Pipeline

Update on the HCV Antiviral Pipeline

by natalia-silvester

Todd S. Wills, MD. SPNS HCV Treatment Expansion I...

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3

by UnicornLove

C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...

by debby-jeon

SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....

SOF + EBR + GZR + RBV

SOF + EBR + GZR + RBV

by test

N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...

by min-jolicoeur

Randomisation. Open-label. W8. * Liver biopsy or ...

HCV Assays: Impact on HCV Studies

HCV Assays: Impact on HCV Studies

by blanko

& . Update on HCV . blood bank protocol. . Ov...

HCV cure by IFN-free DAAs is associated with increased survival in patients with HCV-related HCC

HCV cure by IFN-free DAAs is associated with increased survival in patients with HCV-related HCC

by jovita

Hansen Dang,. 1,2*. Yee Hui Yeo,. 1*. Satoshi Ya...

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology

by badra

Duke University School of Medicine. Durham, North ...

How to optimize treatment of G1 patients?

How to optimize treatment of G1 patients?

by KissesForYou

Prof. G. K. K. Lau 2012. Standard of care (SOC) ...

NS5A and polymerase inhibitors

NS5A and polymerase inhibitors

by LoveBug

Mark Sulkowski, MD. Professor of Medicine. Johns H...

Are (exogenous) interferons

Are (exogenous) interferons

by amey

really necessary?. Peter . Ferenci. Medical Univer...